Circulating adipokines and insulin resistance in subjects with combined cardiac and metabolic syndrome X

被引:7
作者
Liang, Kae-Woei [1 ,2 ,3 ]
Lee, Wen-Jane [4 ,5 ]
Lee, Wen-Lieng [1 ,2 ]
Liao, Ying-Chieh [1 ,2 ,6 ,7 ]
Wang, Kuo-Yang [1 ,2 ,3 ,8 ]
Lee, I. -Te [2 ,8 ,9 ]
Wang, Jun-Sing [2 ,9 ]
Sheu, Wayne H. -H. [2 ,9 ,10 ,11 ]
机构
[1] Taichung Vet Gen Hosp, Ctr Cardiovasc, Taichung 40705, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan
[3] China Med Univ, Dept Med, Taichung, Taiwan
[4] Taichung Vet Gen Hosp, Dept Med Res, Taichung 40705, Taiwan
[5] Tunghai Univ, Taichung, Taiwan
[6] Taichung Tzu Chi Hosp, Taichung, Taiwan
[7] Tzu Chi Univ, Sch Med, Dept Med, Hualien, Taiwan
[8] Chung Shan Med Univ, Dept Med, Taichung, Taiwan
[9] Taichung Vet Gen Hosp, Div Endocrinol & Metab, Dept Med, Taichung 40705, Taiwan
[10] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan
[11] Natl Def Med Ctr, Sch Med, Taipei, Taiwan
关键词
Adiponectin; Cardiac syndrome X (CSX); Combined double syndrome X; Leptin; Metabolic syndrome X (MetX); CARDIOVASCULAR-DISEASE; LEPTIN; ADIPONECTIN; ANGINA; WOMEN; RISK; ASSOCIATION; SEVERITY; RESERVE; OBESITY;
D O I
10.1186/s13098-015-0078-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiac syndrome X (CSX) is characterized by angina pectoris but with patent coronary arteries. Our previous study showed that CSX subjects had decreased serum adiponectin but higher leptin and insulin resistance (IR). However, few studies have investigated circulating adipokines and IR in subjects with combined metabolic syndrome X (MetX) and CSX. Methods: Fifty-nine subjects with CSX were retrospectively enrolled from our cardiac catheterization patient databank. Fifty-four subjects with valvular heart disease or arrhythmia and with normal coronary angiograms were recruited as the non-CSX comparison group. The study subjects were reclassified according to the presence or absence of MetX. Circulating adipokines and degree of IR were measured. Results: Subjects with combined MetX and CSX had a significantly higher HOMA-IR, a higher circulating leptin level (median 8.7 vs. 3.3 ng/mL, p < 0.001), but a lower circulating adiponectin level (median 2.8 vs. 12.3 mu g/mL, p < 0.001) than those without MetX and CSX. In pairwise comparisons, combined MetX and CSX subjects had a similar circulating adipokines and IR index as those who had only either one syndrome X. In a multivariate regression analysis, serum triglycerides (odds ratio 1.011, p = 0.024) and hypertension (odds ratio 14.453, p = 0.003) were independently associated with diagnosis of combined MetX and CSX. Conclusions: Combined MetX and CSX had a significantly higher HOMA-IR, a higher circulating leptin but a lower circulating adiponectin level than those without MetX and CSX. Combined syndrome X did not confer more changes on adipokines or IR index comparing with those with only one syndrome X.
引用
收藏
页数:8
相关论文
共 38 条
  • [1] Coronary Vasodilator Reserve in Untreated and Treated Hypertensive Patients With and Without Left Ventricular Hypertrophy
    Antony, Isabelle
    Nitenberg, Alain
    Foult, Jean-Marc
    Aptecar, Eduardo
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 22 (02) : 514 - 520
  • [2] Beltowski J, 2006, J HYPERTENS, V24, P789
  • [3] Advances in understanding the mechanisms of angina pectoris in cardiac syndrome X
    Beltrame, JF
    [J]. EUROPEAN HEART JOURNAL, 2005, 26 (10) : 946 - 948
  • [4] DEAN JD, 1991, LANCET, V337, P456
  • [5] Association of serum adiponectin levels and coronary flow reserve in women with normal coronary angiography
    Eroglu, Serpil
    Sade, Leyla Elif
    Bozbas, Huseyin
    Haberal, Aysegul
    Ozbicer, Sueleyman
    Demir, Ozlem
    Muderrisoglu, Haldun
    [J]. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2009, 16 (03): : 290 - 296
  • [6] FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
  • [7] Friedman JM, 1998, NUTR REV, V56, pS38
  • [9] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, R
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Cleeman, JI
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    Keller, SA
    Jehle, AJ
    [J]. CIRCULATION, 2002, 106 (25) : 3143 - 3421
  • [10] Grundy SM, 2004, CIRCULATION, V109, P433, DOI [10.1161/01.CIR.0000111245.75752.C6, 10.1161/01.CIR.0000112379.88385.67]